<DOC>
	<DOCNO>NCT02523469</DOCNO>
	<brief_summary>The purpose study define safety tolerability drug combination . The study also define response rate patient advance unresectable NSCLC .</brief_summary>
	<brief_title>ALT-803 Plus Nivolumab Patients With Pretreated , Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This study dose escalation ( Ib ) dose expansion phase ( II ) . The ALT-803 treatment Phase Ib portion study escalate recommend dose level decide . This dose level use phase II portion study . The Phase II potion study include two group : Nivolumab naive Nivolumab progressing . Patients enrol one arm base previous treatment Nivolumab .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis NSCLC present Stage IIIB/Stage IV disease , recurrent disease follow radiation therapy surgical resection . Patient must eligible treatment nivolumab . Patients previously treat nivolumab , pembrolizumab atezolizumab progress eligible . Subjects EGFR ALK mutation eligible disease recurrence progression least one targeted therapy advance metastatic disease . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion . Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 Adequate organ system function within 14 day registration : absolute neutrophil count ≥ 750/μL ( ≥0.75 X 109/L ) platelet count ≥ 100,000/μL ( ≥ 30 X 109/L ) hemoglobin &gt; 8g/dL Total bilirubin &lt; 2.0 x ULN AST &lt; 3.0 X ULN ALT &lt; 3.0 X ULN eGFR &gt; 45mL/min Adequate pulmonary function without clinical sign severe pulmonary dysfunction . Negative serum pregnancy test woman child bear potential . Female participant childbearing potential must adhere use medically accept method birth control prior screen agree continue use study surgically sterilize ( e.g. , hysterectomy tubal ligation ) males must agree use barrier method birth control study . prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCD137 antiCTLA4 antibody allow . New York Heart Association ( NYHA ) Class III IV heart failure , uncontrollable supraventricular arrhythmia , history ventricular arrhythmia , clinical sign severe cardiac dysfunction . Symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within 6 month registration . Marked baseline prolongation QT/corrected QT interval ( e.g . demonstration QTc interval great 500 millisecond ) . Untreated central nervous system ( CNS ) metastases exclude , unless patient meet condition outline protocol . Known autoimmune disease require active treatment . Symptomatic interstitial lung disease ( patient history pneumonitis exclude ) . Prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody Known HIVpositive . Active systemic infection require parenteral antibiotic therapy . All prior infection must resolve follow optimal therapy . Positive hepatitis C serology active hepatitis B infection . Chronic asymptomatic viral hepatitis allow . Women pregnant nursing . Psychiatric illness/social situation would limit compliance study requirement . Any ongoing toxicity prior anticancer treatment , judgment investigator , may interfere study treatment . Anticancer treatment include surgery , radiotherapy , chemotherapy , immunotherapy , investigational therapy within 14 day registration . Other illness opinion investigator would exclude patient participate study , include uncontrolled diabetes mellitus , cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>